Copyright © 2008 Arne Andersson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. M. J. Shapiro, J. R. T. Lakey, E. A. Ryan, et al., “Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen,” The New England Journal of Medicine, vol. 343, no. 4, pp. 230–238, 2000. View at Publisher · View at Google Scholar
2. A. M. J. Shapiro, C. Ricordi, B. J. Hering, et al., “International trial of the Edmonton protocol for islet transplantation,” The New England Journal of Medicine, vol. 355, no. 13, pp. 1318–1330, 2006. View at Publisher · View at Google Scholar · View at PubMed
3. E. L. Opie, “On relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus,” Journal of Experimental Medicine, vol. 5, no. 4, pp. 397–428, 1901. View at Publisher · View at Google Scholar
4. A. Weichselbaum and E. Stangl, “Zur kenntnis der feineren veränderungen des pankreas bei diabetes mellitus,” Wiener Klinische Wochenschrift, vol. 14, pp. 968–972, 1901.
5. J. W. M. Höppener, B. Ahrén, and C. J. M. Lips, “Islet amyloid and type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 343, no. 6, pp. 411–419, 2000. View at Publisher · View at Google Scholar
6. R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn, “Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 8, pp. 3629–3643, 2004. View at Publisher · View at Google Scholar · View at PubMed
7. J. Janson, R. H. Ashley, D. Harrison, S. McIntyre, and P. C. Butler, “The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles,” Diabetes, vol. 48, no. 3, pp. 491–498, 1999. View at Publisher · View at Google Scholar
8. L. Khemtémourian, J. A. Killian, J. W. Höppener, and M. F. E. Engel, “Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in $\beta$-cell death in type 2 diabetes mellitus,” Experimental Diabetes Research, vol. 2008, Article ID 421287, 9 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
9. P. Westermark, C. Wernstedt, E. Wilander, and K. Sletten, “A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas,” Biochemical and Biophysical Research Communications, vol. 140, no. 3, pp. 827–831, 1986. View at Publisher · View at Google Scholar
10. P. Westermark, C. Wernstedt, E. Wilander, D. W. Hayden, T. D. O'Brien, and K. H. Johnson, “Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 11, pp. 3881–3885, 1987. View at Publisher · View at Google Scholar
11. P. Westermark, C. Wernstedt, T. D. O'Brien, D. W. Hayden, and K. H. Johnson, “Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone,” American Journal of Pathology, vol. 127, no. 3, pp. 414–417, 1987.
12. G. J. S. Cooper, A. C. Willis, A. Clark, R. C. Turner, R. B. Sim, and K. B. M. Reid, “Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 23, pp. 8628–8632, 1987. View at Publisher · View at Google Scholar
13. S. Ohagi, M. Nishi, G. I. Bell, J. W. Ensinck, and D. F. Steiner, “Sequences of islet amyloid polypeptide precursors of an old world monkey, the pig-tailed macaque (Macaca nemestrina), and the dog (Canis familiaris),” Diabetologia, vol. 34, no. 8, pp. 555–558, 1991. View at Publisher · View at Google Scholar
14. E. J. P. de Koning, N. L. Bodkin, B. C. Hansen, and A. Clark, “Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population,” Diabetologia, vol. 36, no. 5, pp. 378–384, 1993. View at Publisher · View at Google Scholar
15. K. H. Johnson, C. Wernstedt, T. D. O'Brien, and P. Westermark, “Amyloid in the pancreatic islets of the cougar (Felis concolor) is derived from islet amyloid polypeptide (IAPP),” Comparative Biochemistry and Physiology Part B, vol. 98, no. 1, pp. 115–119, 1991. View at Publisher · View at Google Scholar
16. P. Westermark, Z.-C. Li, G. T. Westermark, A. Leckström, and D. F. Steiner, “Effects of beta cell granule components on human islet amyloid polypeptide fibril formation,” FEBS Letters, vol. 379, no. 3, pp. 203–206, 1996. View at Publisher · View at Google Scholar
17. S. Janciauskiene, S. Eriksson, E. Carlemalm, and B. Ahrén, “B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro,” Biochemical and Biophysical Research Communications, vol. 236, no. 3, pp. 580–585, 1997. View at Publisher · View at Google Scholar · View at PubMed
18. C. Betsholtz, L. Christmansson, U. Engström, et al., “Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species,” FEBS Letters, vol. 251, no. 1-2, pp. 261–264, 1989. View at Publisher · View at Google Scholar
19. C. B. Verchere, D. A. D'Alessio, R. D. Palmiter, et al., “Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 8, pp. 3492–3496, 1996. View at Publisher · View at Google Scholar
20. G. T. Westermark, S. Gebre-Medhin, D. F. Steiner, and P. Westermark, “Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP,” Molecular Medicine, vol. 6, no. 12, pp. 998–1007, 2000.
21. J. W. M. Höppener, C. Oosterwijk, M. G. Nieuwenhuis, et al., “Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model,” Diabetologia, vol. 42, no. 4, pp. 427–434, 1999. View at Publisher · View at Google Scholar
22. W. C. Soeller, J. Janson, S. E. Hart, et al., “Islet amyloid-associated diabetes in obese ${\text{A}}^{(\text{vy})}$/a mice expressing human islet amyloid polypeptide,” Diabetes, vol. 47, no. 5, pp. 743–750, 1998. View at Publisher · View at Google Scholar
23. G. T. Westermark, D. F. Steiner, S. Gebre-Medhin, U. Engström, and P. Westermark, “Pro islet amyloid polypeptide (ProIAPP) immunoreactivity in the islets of langerhans,” Upsala Journal of Medical Sciences, vol. 105, no. 2, pp. 97–106, 2000.
24. G. Westermark, M. B. Arora, N. Fox, et al., “Amyloid formation in response to $\beta$ cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide,” Molecular Medicine, vol. 1, no. 5, pp. 542–553, 1995.
25. E. J. P. de Koning, E. R. Morris, F. M. A. Hofhuis, et al., “Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 18, pp. 8467–8471, 1994. View at Publisher · View at Google Scholar
26. P. Westermark, “Fine structure of islets of Langerhans in insular amyloidosis,” Virchows Archiv A, vol. 359, no. 1, pp. 1–18, 1973. View at Publisher · View at Google Scholar
27. G. T. Westermark, P. Westermark, D. L. Eizirik, et al., “Differences in amyloid deposition in islets of transgenic mice expressing human islet amyloid polypeptide versus human islets implanted into nude mice,” Metabolism, vol. 48, no. 4, pp. 448–454, 1999. View at Publisher · View at Google Scholar
28. G. T. Westermark, P. Westermark, A. Nordin, E. Törnelius, and A. Andersson, “Formation of amyloid in human pancreatic islets transplanted to the liver and spleen of nude mice,” Upsala Journal of Medical Sciences, vol. 108, no. 3, pp. 193–204, 2003.
29. S. E. Kahn and P. A. Halban, “Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM,” Diabetes, vol. 46, no. 11, pp. 1725–1732, 1997. View at Publisher · View at Google Scholar
30. R. S. Jackson, J. W. M. Creemers, S. Ohagi, et al., “Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene,” Nature Genetics, vol. 16, no. 3, pp. 303–306, 1997. View at Publisher · View at Google Scholar · View at PubMed
31. J. F. Paulsson, S. W. Schultz, M. Köhler, I. Leibiger, P. O. Berggren, and G. T. Westermark, “Real-time monitoring of apoptosis by caspase-3-like protease induced FRET reduction triggered by amyloid aggregation,” Experimental Diabetes Research, vol. 2008, Article ID 865850, 12 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
32. J. F. Paulsson and G. T. Westermark, “Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation,” Diabetes, vol. 54, no. 7, pp. 2117–2125, 2005. View at Publisher · View at Google Scholar
33. L. Marzban, C. J. Rhodes, D. F. Steiner, L. Haataja, P. A. Halban, and C. B. Verchere, “Impaired ${\text{NH}}_2$-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death,” Diabetes, vol. 55, no. 8, pp. 2192–2201, 2006. View at Publisher · View at Google Scholar · View at PubMed
34. L. Jansson, D. L. Elzirik, D. G. Pipeleers, L. A. Borg, C. Hellerström, and A. Andersson, “Impairment of glucose-induced insulin secretion in human pancreatic islets transplanted to diabetic nude mice,” Journal of Clinical Investigation, vol. 96, no. 2, pp. 721–726, 1995. View at Publisher · View at Google Scholar · View at PubMed
35. B. Volk, “Pathology of the diabetic pancreas,” in Diabetes Mellitus: Theory and Practice, H. Rifkin and D. Porte, Jr., Eds., pp. 341–345, Elsevier, Philadelphia, Pa, USA, 1990.
36. O. Korsgren, L. Jansson, and A. Andersson, “Effects of hyperglycemia on function of isolated mouse pancreatic islets transplanted under kidney capsule,” Diabetes, vol. 38, no. 4, pp. 510–515, 1989. View at Publisher · View at Google Scholar
37. D. L. Eizirik, L. Jansson, M. Flodström, C. Hellerström, and A. Andersson, “Mechanisms of defective glucose-induced insulin release in human pancreatic islets transplanted to diabetic nude mice,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 8, pp. 2660–2663, 1997. View at Publisher · View at Google Scholar
38. J. F. Paulsson, A. Andersson, P. Westermark, and G. T. Westermark, “Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (ProIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets,” Diabetologia, vol. 49, no. 6, pp. 1237–1246, 2006. View at Publisher · View at Google Scholar · View at PubMed
39. P. Westermark, D. L. Eizirik, D. G. Pipeleers, C. Hellerström, and A. Andersson, “Rapid deposition of amyloid in human islets transplanted into nude mice,” Diabetologia, vol. 38, no. 5, pp. 543–549, 1995. View at Publisher · View at Google Scholar
40. P.-O. Carlsson, F. Palm, and G. Mattsson, “Low revascularization of experimentally transplanted human pancreatic islets,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 12, pp. 5418–5423, 2002. View at Publisher · View at Google Scholar
41. S. Bohman, A. Andersson, and A. King, “No differences in efficacy between noncultured and cultured islets in reducing hyperglycemia in a nonvascularized islet graft model,” Diabetes Technology and Therapeutics, vol. 8, no. 5, pp. 536–545, 2006. View at Publisher · View at Google Scholar · View at PubMed
42. S. Bohman, P. Westermark, A. Andersson, and G.T. Westermark, “Amyloid formation in transplanted microencapsulated islets,” in Proceedings of the 18th EASD Islet Study Group Symposium, p. 17, Rome, Italy, September 2008.
43. G. T. Westermark, P. Westermark, C. Berne, and O. Korsgren, “Widespread amyloid deposition in transplanted human pancreatic islets,” The New England Journal of Medicine, vol. 359, no. 9, pp. 977–979, 2008. View at Publisher · View at Google Scholar · View at PubMed
44. S. Zraika, R. L. Hull, J. Udayasankar, et al., “Glucose- and time-dependence of islet amyloid formation in vitro,” Biochemical and Biophysical Research Communications, vol. 354, no. 1, pp. 234–239, 2007. View at Publisher · View at Google Scholar · View at PubMed
45. L. M. Dember, P. N. Hawkins, B. P. C. Hazenberg, et al., “Eprodisate for the treatment of renal disease in AA amyloidosis,” The New England Journal of Medicine, vol. 356, no. 23, pp. 2349–2360, 2007. View at Publisher · View at Google Scholar · View at PubMed